Next Generation sPLA2 Inhibitors
Introduction
We also have next generation sPLA2 inhibitor, A-003, in preclinical development for existing target indications as well as other therapeutic areas. A-003 has shown increased potency against sPLA2 and favorable characteristics in preclinical studies. We plan to file an investigational new drug application for A-003 in the future.
